目的探讨睾丸原发性弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中MyD88及CD79B基因突变及意义。方法回顾性分析15例睾丸原发性DLBCL的临床病理学特点,采用免疫组化及Sanger测序法检测原发性DLBCL中MyD88及CD79 B基因突变...目的探讨睾丸原发性弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中MyD88及CD79B基因突变及意义。方法回顾性分析15例睾丸原发性DLBCL的临床病理学特点,采用免疫组化及Sanger测序法检测原发性DLBCL中MyD88及CD79 B基因突变,分析MyD88及CD79B基因突变与肿瘤临床病理学特点、NF-κB蛋白在细胞核表达之间的关系。结果免疫组化显示15例DLBCL均为非生发中心B(non germinal center B,non-GCB)细胞型,4例存在CD79B基因Y196位点突变(26.7%),7例存在MyD88基因L265位点突变(46.7%),3例同时存在CD79B及MyD88基因突变(20%)。8例患者获得随访,未发现CD79B及MyD88基因突变与预后的相关性。结论中国人睾丸原发性DLBCL中存在较高的CD79B基因Y196位点和(或)MyD88基因L265位点突变,为针对这些突变基因的分子靶向治疗提供依据。展开更多
目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中MYD88、CD79B基因突变与其临床病理特征及预后的相关性。方法对2016年10月~2020年7月苏州大学附属第三医院89例经病理学诊断的DLBCL进行回顾性分析。应用二代测序技...目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中MYD88、CD79B基因突变与其临床病理特征及预后的相关性。方法对2016年10月~2020年7月苏州大学附属第三医院89例经病理学诊断的DLBCL进行回顾性分析。应用二代测序技术检测患者基因变异情况,并分析MYD88、CD79B基因与临床病理特征及预后的关系。结果89例DLBCL中MYD88基因突变、CD79B基因突变和MYD88/CD79B基因双突变的频率分别为20.2%、21.3%、6.7%。MYD88基因在非生发中心B细胞(non-germinal center B-cell-like,non-GCB)型、BCL-2阳性、c-MYC/BCL-2双阳性和Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。CD79B基因在non-GCB型及Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。MYD88/CD79B基因双突变在c-MYC/BCL-2双阳性及Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。MYD88基因突变和MYD88/CD79B基因双突变病例在中期疗效评估时其完全缓解率均低于非突变病例(P<0.05)。单因素Kaplan-Meier生存分析显示:MYD88基因突变和MYD88/CD79B基因双突变患者的总生存期及无进展生存期均低于非突变组(P<0.05)。结论MYD88基因突变DLBCL更常见于non-GCB型,具有较高的Ki-67增殖指数、BCL-2阳性和c-MYC/BCL-2共阳性的特点;CD79B基因突变DLBCL更常见于non-GCB型,Ki-67增殖指数较高;MYD88/CD79B基因双突变DLBCL具有较高的Ki-67增殖指数和c-MYC/BCL-2共阳性的特点。MYD88基因突变、MYD88/CD79B基因双突变影响DLBCL患者化疗效果及长期生存。展开更多
Transformation-temperature-hydrogen pressure phase diagram was constructed for a Nd15Fe79B6 alloy in order to estimate appropriate conditions for hydrogenation, disproportionation, desorption and recombination reacti...Transformation-temperature-hydrogen pressure phase diagram was constructed for a Nd15Fe79B6 alloy in order to estimate appropriate conditions for hydrogenation, disproportionation, desorption and recombination reaction （the HDDR）. Optimised recom- bination time （the highest coercivity） was found to be 10 rain. for 5 g samples processed at 740 ℃. Several HDDR processes were carried out at 30 kPa of hydrogen pressure at various temperatures. No correlation between magnetic propertiec and a direction of measurement was observed for the samples processed at 740 ℃. Remanence anisotropy was induced along an alignment direction when the temperature of the HDDR process was increased up to 800 ℃ and 850℃ for 〈100 gm and 100-160 p.m particles, respec- tively. Simultaneously, a small drop in coercivity was observed in the direction of alignment for 〈100 pm particles, but no for 100-160 grn particles. Furthermore, probably an ordered phase was found by TEM microstructure analysis in the bulk sample dis- proportionated at 850 ℃ under 150 kPa of hydrogen. Grains with antiphase domains were observed and corresponding electron dif- fraction patterns were resolved, likely indicating superlattice structures.展开更多
BACKGROUNDOver the past 20 years,we have gained a deep understanding of the biologicalheterogeneity of diffuse large B cell lymphoma(DLBCL)and have developed arange of new treatment programs based on the characteristi...BACKGROUNDOver the past 20 years,we have gained a deep understanding of the biologicalheterogeneity of diffuse large B cell lymphoma(DLBCL)and have developed arange of new treatment programs based on the characteristics of the disease,bringing us to the era of immune-chemotherapy.However,the effectiveness andmolecular mechanisms of targeted-immunotherapy remain unclear in DLBCL.Targeted-immunotherapy may be beneficial for specific subgroups of patients,thus requiring biomarker assessment.CASE SUMMARYHere,we report a case of MCD subtype DLBCL with MYD88L265P and CD79Bmutations,considered in the initial stage as lymphoplasmic lymphoma(LPL)orWaldenstrom macroglobulinemia(WM).Flow cytometry supported this view;however,the immunohistochemical results of the lymph nodes overturned theabove diagnosis,and the patient was eventually diagnosed with MCD subtypeDLBCL.The presence of a monoclonal IgM component in the serum and infiltrationof small lymphocytes with a phenotype compatible with WM into the bonemarrow led us to propose a hypothesis that the case we report may have transformedfrom LPL/WM.CONCLUSIONThis highlights the possible transformation from WM to DLBCL,CD79B mutationmay be a potential biomarker for predicting this conversion.展开更多
In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotr...In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotrexate(HD-MTX)as a therapeutic intervention for primary central nervous system lymphoma(PCNSL).The study involves a retrospective analysis of 19 PCNSL patients,highlighting clinicopathological characteristics,treatment outcomes,and genomic biomarkers.The results indicate the combination’s good tolerance and strong antitumor activity,with an 84.2%overall response rate.The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL,particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B.Furthermore,the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring.In essence,the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL.The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes.While the findings suggest promise,the study’s limitations should be considered,and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL.展开更多
文摘目的探讨睾丸原发性弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)中MyD88及CD79B基因突变及意义。方法回顾性分析15例睾丸原发性DLBCL的临床病理学特点,采用免疫组化及Sanger测序法检测原发性DLBCL中MyD88及CD79 B基因突变,分析MyD88及CD79B基因突变与肿瘤临床病理学特点、NF-κB蛋白在细胞核表达之间的关系。结果免疫组化显示15例DLBCL均为非生发中心B(non germinal center B,non-GCB)细胞型,4例存在CD79B基因Y196位点突变(26.7%),7例存在MyD88基因L265位点突变(46.7%),3例同时存在CD79B及MyD88基因突变(20%)。8例患者获得随访,未发现CD79B及MyD88基因突变与预后的相关性。结论中国人睾丸原发性DLBCL中存在较高的CD79B基因Y196位点和(或)MyD88基因L265位点突变,为针对这些突变基因的分子靶向治疗提供依据。
文摘目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中MYD88、CD79B基因突变与其临床病理特征及预后的相关性。方法对2016年10月~2020年7月苏州大学附属第三医院89例经病理学诊断的DLBCL进行回顾性分析。应用二代测序技术检测患者基因变异情况,并分析MYD88、CD79B基因与临床病理特征及预后的关系。结果89例DLBCL中MYD88基因突变、CD79B基因突变和MYD88/CD79B基因双突变的频率分别为20.2%、21.3%、6.7%。MYD88基因在非生发中心B细胞(non-germinal center B-cell-like,non-GCB)型、BCL-2阳性、c-MYC/BCL-2双阳性和Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。CD79B基因在non-GCB型及Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。MYD88/CD79B基因双突变在c-MYC/BCL-2双阳性及Ki-67增殖指数高的病例中具有较高的突变频率(P<0.05)。MYD88基因突变和MYD88/CD79B基因双突变病例在中期疗效评估时其完全缓解率均低于非突变病例(P<0.05)。单因素Kaplan-Meier生存分析显示:MYD88基因突变和MYD88/CD79B基因双突变患者的总生存期及无进展生存期均低于非突变组(P<0.05)。结论MYD88基因突变DLBCL更常见于non-GCB型,具有较高的Ki-67增殖指数、BCL-2阳性和c-MYC/BCL-2共阳性的特点;CD79B基因突变DLBCL更常见于non-GCB型,Ki-67增殖指数较高;MYD88/CD79B基因双突变DLBCL具有较高的Ki-67增殖指数和c-MYC/BCL-2共阳性的特点。MYD88基因突变、MYD88/CD79B基因双突变影响DLBCL患者化疗效果及长期生存。
基金Project supported by the National Centre for Research and Development(INNOTECH-K2/IN2/18/181960/NCBR/13)
文摘Transformation-temperature-hydrogen pressure phase diagram was constructed for a Nd15Fe79B6 alloy in order to estimate appropriate conditions for hydrogenation, disproportionation, desorption and recombination reaction （the HDDR）. Optimised recom- bination time （the highest coercivity） was found to be 10 rain. for 5 g samples processed at 740 ℃. Several HDDR processes were carried out at 30 kPa of hydrogen pressure at various temperatures. No correlation between magnetic propertiec and a direction of measurement was observed for the samples processed at 740 ℃. Remanence anisotropy was induced along an alignment direction when the temperature of the HDDR process was increased up to 800 ℃ and 850℃ for 〈100 gm and 100-160 p.m particles, respec- tively. Simultaneously, a small drop in coercivity was observed in the direction of alignment for 〈100 pm particles, but no for 100-160 grn particles. Furthermore, probably an ordered phase was found by TEM microstructure analysis in the bulk sample dis- proportionated at 850 ℃ under 150 kPa of hydrogen. Grains with antiphase domains were observed and corresponding electron dif- fraction patterns were resolved, likely indicating superlattice structures.
文摘BACKGROUNDOver the past 20 years,we have gained a deep understanding of the biologicalheterogeneity of diffuse large B cell lymphoma(DLBCL)and have developed arange of new treatment programs based on the characteristics of the disease,bringing us to the era of immune-chemotherapy.However,the effectiveness andmolecular mechanisms of targeted-immunotherapy remain unclear in DLBCL.Targeted-immunotherapy may be beneficial for specific subgroups of patients,thus requiring biomarker assessment.CASE SUMMARYHere,we report a case of MCD subtype DLBCL with MYD88L265P and CD79Bmutations,considered in the initial stage as lymphoplasmic lymphoma(LPL)orWaldenstrom macroglobulinemia(WM).Flow cytometry supported this view;however,the immunohistochemical results of the lymph nodes overturned theabove diagnosis,and the patient was eventually diagnosed with MCD subtypeDLBCL.The presence of a monoclonal IgM component in the serum and infiltrationof small lymphocytes with a phenotype compatible with WM into the bonemarrow led us to propose a hypothesis that the case we report may have transformedfrom LPL/WM.CONCLUSIONThis highlights the possible transformation from WM to DLBCL,CD79B mutationmay be a potential biomarker for predicting this conversion.
文摘In this editorial,we comment on the article by Wang et al.This manuscript explores the potential synergistic effects of combining zanubrutinib,a novel oral inhibitor of Bruton’s tyrosine kinase,with high-dose methotrexate(HD-MTX)as a therapeutic intervention for primary central nervous system lymphoma(PCNSL).The study involves a retrospective analysis of 19 PCNSL patients,highlighting clinicopathological characteristics,treatment outcomes,and genomic biomarkers.The results indicate the combination’s good tolerance and strong antitumor activity,with an 84.2%overall response rate.The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL,particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B.Furthermore,the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring.In essence,the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL.The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes.While the findings suggest promise,the study’s limitations should be considered,and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL.
